Before death occurs from advanced prostate cancer, all patients pass through a ‘hormone resistant’ phase of the disease (HRPC). A large proportion of patients with advanced prostate cancer on hormonal therapy are managed in the Urology Outpatient Department, albeit with multidisciplinary input into their care. Chemotherapy for HRPC has now been shown to increase survival and quality of life and many novel agents are now undergoing Phase I and Phase II trials. The timely and appropriate referral of patients for chemotherapy, however, is essential in order to optimise patients' care and use chemotherapy wisely. This article addresses many of these practical issues.
ShelleyMHarrisonCColesBStaffurthJWiltTJMasonMD. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No.: CD005247. DOI:10.1002/14651858.CD005247. pub2.
2.
AttardGReidAHYapTARaynaudFDowsettMSettatreeSPhase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. JCO Early Release, published online ahead of print Jul 21 2008. J Clin Oncol, 10.1200/JCO.2007.15.9749.
3.
ArmstrongAJGeorgeDJ. Satraplatin in the treatment of hormone-refractory metastatic prostate cancer. Ther Clin Risk Manag2007;3:877–83.
4.
DawsonNA. Epothilones in prostate cancer: review of clinical experience. Ann Oncol2007;18(Suppl 5):v22–7.
5.
PatelPHKocklerDR. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann Pharmacother2008;42:91–8.
6.
WardJEMcNeelDG. GVAX: an allogeneic, whole-cell, GMCSF-secreting cellular immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther2007;7:1893–902.
7.
SmallEJTchekmedyianNSRiniBIFongLLowyIAllisonJP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res2007;13:1810–5.
National Collaborating Centre for Cancer. Prostate cancer: diagnosis and treatment. National Institute for Clinical Health and Excellence full guideline. February 2008 (www.nice.org.uk/nicemedia/pdf/CG58FullGuideline.pdf; accessed 11 August 2008).
10.
National Institute for Clinical Excellence. Improving outcomes in urological cancers. The manual. Guidance on Cancer Services. September 2002.
11.
National Institute for Clinical Health and Excellence. Docetaxel for the treatment of metastatic hormone-refractory prostate cancer. Technology Appraisal 101. June 2006 (www.nice.org.uk/nicemedia/pdf/TA101guidance.pdf; accessed 11 August 2008).
12.
OhWKTullyPKantoffPWReganMM. Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate cancer. Cancer2003;97:2171–9.
13.
YagodaAPetrylakD. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer1993;71(3 Suppl):1098–109.
14.
TannockIFde WitRBerryWRHortyJPluzanskaAChiAMDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med2004;351:1502–12.
15.
EymardJCPriouFZannettiARavaudALepilléDKerbratPRandomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. Ann Oncol2007;18:1064–70.
16.
PetrylakDPTangenCMHussainMHLaraPNJrJonesJATaplinMEDocetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med2004;351:1513–20.
17.
BeerTMRyanCWVennerPMPetrylakDPChattaGSRuetherJDDouble-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol2007;25:669–74.
18.
DahutWLGulleyJLArlenPMLiuYFedenkoKMSteinbergSMRandomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol2004;22:2532–9.
19.
BertholdDRPondGRSobanFde WitREisenbergerMTannockIF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol2008;26:242–5.
20.
National Institute for Clinical Excellence. Improving supportive and palliative care for adults with cancer. The Manual. March 2004.
EchlinKNReesCE. Information needs and information-seeking behaviors of men with prostate cancer and their partners: a review of the literature. Cancer Nurs2002;25:35–41.
26.
National Institute for Health and Clinical Excellence. Understanding NICE guidance. Prostate cancer. February 2008.
